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ABSTRACT
The microdosimetric kinetic model (MKM) is widely used for estimating relative biological effectiveness (RBE)-
weighted doses for various radiotherapies because it can determine the surviving fraction of irradiated cells based on
only the lineal energy distribution, and it is independent of the radiation type and ion species. However, the applic-
ability of the method to proton therapy has not yet been investigated thoroughly. In this study, we validated the
RBE-weighted dose calculated by the MKM in tandem with the Monte Carlo code PHITS for proton therapy by
considering the complete simulation geometry of the clinical proton beam line. The physical dose, lineal energy distri-
bution, and RBE-weighted dose for a 155MeV mono-energetic and spread-out Bragg peak (SOBP) beam of 60 mm
width were evaluated. In estimating the physical dose, the calculated depth dose distribution by irradiating the mono-
energetic beam using PHITS was consistent with the data measured by a diode detector. A maximum difference of
3.1% in the depth distribution was observed for the SOBP beam. In the RBE-weighted dose validation, the calculated
lineal energy distributions generally agreed well with the published measurement data. The calculated and measured
RBE-weighted doses were in excellent agreement, except at the Bragg peak region of the mono-energetic beam, where
the calculation overestimated the measured data by ~15%. This research has provided a computational microdosi-
metric approach based on a combination of PHITS and MKM for typical clinical proton beams. The developed
RBE-estimator function has potential application in the treatment planning system for various radiotherapies.
Keywords: proton therapy; relative biological effectiveness; PHITS; microdosimetric kinetic model
INTRODUCTION
Radiotherapy is used worldwide for non-invasive cancer treatment.
Before performing radiotherapy, it is necessary to simulate the dose
distribution in the patient’s body, known as treatment planning,
through by a treatment planning system (TPS). In a TPS, the dose
distribution in the target and normal tissue surrounding the target is
estimated by a dose calculation algorithm. Although the dose calcula-
tion algorithm differs for each radiation type, Monte Carlo calculations
are considered to be the most accurate. Monte Carlo simulations are
employed in TPSs for radiotherapies such as X-ray therapy, charged
particle therapy and boron neutron capture therapy (BNCT) [1–8].
Two different doses must be evaluated for charged particle
therapy and BNCT: one is the physical dose, known as the
absorbed dose, and the other is the biological dose, which takes
into account the biological effectiveness of the radiation type.
The biological dose is determined by multiplying the relative bio-
logical effectiveness (RBE) by the physical dose; thus, it is called
the RBE-weighted dose. The RBE values employed in TPSs for
carbon ion therapy were determined using the surviving fraction
of cells as the biological end point. Several biophysical models for
estimating the surviving fraction of cells irradiated by various
radiation types have been developed, such as the local effect
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model (LEM) [9, 10], the repair-misrepair-ﬁxation model [11],
and the microdosimetric kinetic model (MKM) [12, 13].
The MKM is one of the most widely used models in radiation
biology because it can determine the surviving fractions of cells irra-
diated by any type of radiation, based on the dose distribution of
the lineal energy [14], y, and it is independent of the radiation type
and ion species. Thus, it has been used to estimate the RBE in vari-
ous radiotherapies, such as proton therapy [15], carbon ion therapy
[16–21], BNCT [22], and X-ray therapy [23]. In these studies, the
dose distributions of y were evaluated by measurements based on
the tissue-equivalent proportional counter (TEPC) or simulations
based on Monte Carlo particle transport codes. Considering that it
is impractical to measure the dose distribution of y for all irradiation
conditions in realistic radiotherapy ﬁelds by TEPC, the use of
MKM alongside Monte Carlo simulations is more suitable for TPS
implementation. However, for proton beam therapy, only a few
studies on simulation-based RBE estimation have been reported [8,
24]. One reason for this is that most clinical proton therapy facilities
use a constant value of 1.1 as the clinical RBE. On the other hand,
recent studies have reported some variation in the RBE value
according to the depth of the clinical proton beam (i.e. the depth of
the spread-out Bragg peak: SOBP) [25–29]. Therefore, multilateral
approaches such as MKM coupled with various Monte Carlo simu-
lations are required for precise estimation of RBE.
In this research, the Particle and Heavy Ion Transport code
System (PHITS) [30] was coupled with MKM because it has a
function to calculate the dose distribution of y in a short computa-
tional time, called the microdosimetric function [31, 32]. The accur-
acy of PHITS coupled with MKM for estimating the RBE-weighted
dose has been examined for carbon ion therapy [17, 19] and BNCT
[22], but not for proton therapy. For the validation, a full simula-
tion reproducing the beam line of the Proton Medical Research
Center (PMRC) at the University of Tsukuba [33] was performed.
The physical doses as well as their y distributions along with beam
penetration were calculated, and these were converted to the RBE-
weighted dose using MKM. These simulation results were com-
pared with the corresponding published experimental data [15].
Based on the results obtained in this study, the RBE-weighted
dose in the clinical proton beam line can be estimated using PHITS
coupled with MKM. This is expected to be a very useful tool for
treatment planning in various clinical conditions.
MATERIALS AND METHODS
This study ﬁrst validated the physical dose estimated by PHITS,
and then focused on the RBE-weighted dose estimated by PHITS
coupled with MKM.
Validation of physical dose with full mock-up simulation
geometry of the clinical proton beam line
In the PHITS simulation, equipment such as a proﬁle monitor, 1st
scatterer, 2nd scatterer, sub-monitor, ridge ﬁlter, ﬂatness monitor,
multi-leaf collimator, main monitor, and middle collimator were
placed upstream of the beam. All monitors were made of polyimide
thin ﬁlm with copper. The proton pencil beam was ﬁrst broadened
by the 1st scatterer, which was constructed from tungsten. The 2nd
scatterer was made of lead alloy and plastic resin (acrylonitrile buta-
diene styrene). The ridge ﬁlter unit was made of aluminum alloy
and was only used for the SOBP beam. In the simulation, each
ridge-shaped bar was stacked as a multilayer structure, with thinner
layers than the actual dimensions to calculate the inﬂuence of mul-
tiple Coulomb scattering in aluminum alloy more accurately. All col-
limators were made of brass. Patient-speciﬁc equipment (such as a
range shifter, range compensator or patient collimator) was not
considered (Fig 1).
The physical depth dose distribution produced by a 155 MeV
beam was calculated by PHITS using the [T-deposit] function [34],
which computes the deposition energy only from charged particles,
i.e. the Kerma approximation was not employed in this study. The
use of event generator mode is indispensable in the function. The
nuclear reactions induced by neutrons above 20 MeV and protons
were simulated by the intranuclear cascade model INCL4.6 [35],
while those induced by neutrons below 20MeV were simulated by
the event generator mode version 2 [36] coupled with the nuclear
data library JENDL-4.0 [37]. The angle straggling and energy strag-
gling of protons are also considered by PHITS. The ATIMA model
[38] was used for stopping power calculation. The EGS5 algorithm
[39] was used for analyzing the motion of electrons, positrons and
photons. The calculation mesh for the depth dose distribution had a
step size of 2.5 mm in radius and 1 mm in depth. The simulation
history numbers for the mono-energetic beam and the SOBP beam
were set to 750 million particles and 2 billion particles, respectively.
The physical depth dose distribution data for the 155 MeV
mono-energetic beam and the SOBP beam at PMRC measured
using an electron diode ﬁeld detector (EFD 3G-pSi, IBA
Dosimetry) were used for comparison.
Validation of the RBE-weighted dose by PHITS with
implemented MKM
The calculation procedure for the RBE based on MKM coupled
with PHITS was described in detail in reference [17]; thus, only an
outline of the procedure is given here.
The RBE for surviving fraction S in a complex radiation ﬁeld can
be obtained by the equation:
Fig. 1. Calculation geometry used for the physical and RBE-weighted dose validation of the clinical proton beam therapy.
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where DX(S) and DC(S) are the doses used to obtain surviving frac-
tion S in the X-ray and complex radiation ﬁelds, respectively.
According to the linear quadratic (LQ) model, the dose used to
obtain surviving fraction S, D(S), can be determined by the
equation:
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where α and β are the linear and quadratic coefﬁcients of the LQ
model, respectively. In the MKM, β can be regarded as a parameter
independent of radiation quality, while α can be estimated from:
α = α + β ( )⁎z 30 1D
where α0 is a constant that represents the slope of the surviving
fraction curve in the limit of LET = 0. The parameter ⁎z1D denotes
the saturation-corrected dose-mean speciﬁc energy, which can be
calculated by:
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where ρ and rd are the density and radius of domain, respectively, y0
is the saturation parameter, and d(y) is the dose distribution of y
calculated by PHITS.
In this study, RBE at each depth was evaluated by substituting 0.1
for S in Eq. (1), i.e. the RBE for the 10% surviving fraction was
employed in the RBE-weighted dose estimation irrespective of the
dose and dose rate. It is known that RBE depends not only on radi-
ation quality but also largely on dose and dose rate. However, we
ignored the latter factors in the same manner as done in the RBE-
estimation method adopted for the HIMAC passive beam [40] as
well as clinical proton therapy. The dose distribution of y, yd(y), for
the mono-energetic and SOBP beams was calculated using the micro-
dosimetric function of PHITS at 1 mm depth intervals. On the other
hand, the active volume size of TEPC (diameter: 12.7 mm) is larger
than the spatial resolution of PHITS. Therefore, the yd(y) spectrum
calculated by PHITS at each depth was averaged over a range of
±1.5 mm centered at each interest depth of the beam axis. The diam-
eter of 0.564 μm was selected to deﬁne the microdosimetric sensitive
region to calculate yd(y) and the RBE-weighted dose based on the
MKM. In estimating the RBE-weighted doses, the RBE for the 10%
surviving fractions was determined from the calculated yd(y) for each
depth, using the MKM parameters evaluated from the experimental
surviving fractions of human salivary gland (HSG) cells irradiated
with C, Ne, Si and Fe ions [16]. We employed 200 kVp X-rays (α
value: 0.19 Gy−1, β value: 0.05 Gy−2 in the linear quadratic model) as
reference radiation for calculating RBE [15, 16]. The values of α0, β,
domain radius (rd) and saturation parameter (y0) for the MKM para-
meters used in this study were set as 0.155 Gy−1, 0.0615 Gy−2,
0.282 μm and 93.4 keV/μm, respectively, while those used to estimate
the RBE-weighted doses were set as α0: 0.13 Gy−1, β: 0.05 Gy−2, rd:
0.42 μm, and y0: 150 keV/μm, as depicted in Figs 6 and 7. Note that
we employed the same MKM parameters as used for carbon ion ther-
apy [32], i.e. the parameters were not optimized for proton therapy.
RESULTS
Physical dose validation
Figure 2 shows the physical depth dose distribution in a water phan-
tom for the 155 MeV mono-energetic beam. In Fig. 2, the present
study data (PHITS calculation and diode detector) are compared
with the published data (TEPC, ionization chamber) [15]. The stat-
istical uncertainties for the calculated values up to the distal fall-off
of the Bragg peak were below 0.5%. Both the calculated and mea-
sured dose distributions in the present study were normalized at the
Bragg-peak as 2 Gy. A maximum difference of 2.4% between the
PHITS calculation and measurement with the electron diode
detector was observed at the entrance of the water phantom.
Figure 3 compares the physical depth dose distribution of the
present study data (PHITS calculation and diode detector) with the
published data for the 155 MeV SOBP beam [15]. Both the calcu-
lated and measured dose distributions in the present study were
normalized at the center of the SOBP as 2 Gy. The statistical uncer-
tainties for the calculated values up to the distal fall-off of the SOBP
were below 0.5%. A maximum difference of 3.1% between the
PHITS calculation and the measured data was observed at the distal
of the SOBP.
RBE-weighted dose validation
The yd(y) distributions calculated by PHITS were compared with the
measured yd(y) at typical depths obtained by TEPC measurement.
Note that the microdosimetric site diameter differed between the
published experimental value and the PHITS calculation. Due to the
difference in the site diameter, the calculated y distribution slightly
shifted; however, it did not have much impact. Figures 4 and 5 com-
pare the yd(y) distributions at three depths (22 mm, 102 mm and
132mm) in the water phantom in the case of irradiation by the
155MeV mono-energetic and SOBP beams, respectively. These
depths correspond to the plateau region, the proximal of the Bragg
peak region, and the Bragg peak region, respectively, for the mono-
energetic beam, and the proximal, the center and the distal of the
SOBP, respectively, for the SOBP beam. The yd(y) distribution shifts
to higher y values at deeper regions because slower protons deposit
more of their energy locally.
The calculated yd(y) distributions were generally in good agree-
ment with the measurement data, except in higher y regions
observed at the Bragg peak of the mono-energetic beam, where the
calculation slightly overestimated the measured data.
Figures 6 and 7 compare the depth distributions of the RBE-
weighted dose for the 155MeV mono-energetic and SOBP beams,
respectively. For the mono-energetic beam, the calculated dose distri-
butions were normalized with the same factors used for normalizing
the physical doses as shown in Fig. 2. With regard to the SOBP beam,
the calculated RBE-weighted dose at the center of the SOBP was nor-
malized to 2 Gy in order to compare it with the published data. The
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statistical uncertainties for all calculation data were below 0.8% up to
the distal fall-off of the depth dose distribution. There was excellent
agreement between the calculated and measured data, except in the
Bragg peak region of the mono-energetic beam, where the calculation
overestimated the measured data by 14.7%. This overestimation can
possibly be attributed to the difference between the spatial resolutions
of the calculation and the measurement because the physical doses
dramatically vary with depth at the Bragg peak and overestimation of
the RBE value due to the disagreement between the yd(y) distribu-
tions at higher y regions. Both the calculations and measurements
suggested that the RBE-weighted doses in the SOBP region gradually
increase with an increase in depth.
DISCUSSION
In this research, we calculated physical and RBE-weighted dose dis-
tributions in a proton therapy facility with a fully mocked-up Monte
Carlo calculation geometry. The physical dose distributions, yd(y)
distributions, and RBE-weighted dose of the 155 MeV mono-
energetic and SOBP beams calculated by PHITS agreed well with
Fig. 2. Comparison of depth physical dose distribution in the water phantom after irradiation by the 155 MeV mono-energetic
proton beam. The circles and lines represent the published data and present data, respectively. The vertical axis shows the
physical dose normalized at the Bragg peak as 2 Gy.
Fig. 3. Comparison of depth physical dose distribution in the water phantom after irradiation by the 155 MeV proton beam
with 60 mm SOBP width. The circles and lines represent the published data and present data, respectively. The vertical axis
shows the physical dose normalized at the center of the SOBP as 2 Gy.
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the experimental data, indicating that PHITS accurately simulates
the proton beam line used for clinical proton therapy.
RBE-weighted dose at the entrance of the water
phantom for a mono-energetic beam
It is evident from Fig. 6 that the RBE-weighted dose at the entrance
of a water phantom irradiated by a mono-energetic proton beam
was slightly lower than 100% (93.9%), indicating that the RBE at
the location was smaller than 1.0. This is because the ionization
densities around the trajectory of the high-energy protons are gener-
ally smaller than those around the reference radiation adopted in
this study, i.e. 200 kVp X-rays. Note that the RBE would be closer
to 1.0 when higher energy photons such as γ-rays from 60Co are
employed as the reference radiation, because the surviving fractions
for photon irradiations generally become smaller with decreasing
photon energy owing to the increase in dose-mean lineal energy
[23]. This difference can be properly expressed by the MKM.
Depth distribution of the survival fraction for the clinical
SOBP beam
We also estimated the corresponding depth distribution of the sur-
vival fraction of the HSG cells for the clinical SOBP beam from the
y distributions calculated using the microdosimetric function of
PHITS. For that purpose, the α value and ⁎z1D at each depth were
Fig. 4. Comparison of yd(y) distributions in the water phantom after irradiation by the 155 MeV mono-energetic proton
beam. The circles and lines represent the published data measured by TEPC [15] and calculated by PHITS, respectively.
Fig. 5. Comparison of yd(y) distributions in the water phantom after irradiation by the 155MeV proton beam with 60 mm
SOBP width. The circles and lines represent the published data measured by TEPC [15] and calculated by PHITS, respectively.
Validation of RBE-weighted dose for proton therapy • 95
Downloaded from https://academic.oup.com/jrr/article-abstract/59/1/91/4566179
by University of Tsukuba user
on 06 March 2018
calculated from the y distributions using Eqs (3) and (4), respect-
ively. Figure 8 shows the depth distributions of the survival fraction
for the clinical SOBP beam. The absolute values of the absorbed
doses were normalized to 2 Gy at the SOBP center, or to yield 10%
cell survival, i.e. 4.77 Gy, at the target in the center of SOBP.
The calculated α values at each depth obtained by this study
were similar to the values reported by Kase et al. [15].
Advantage of a y-based RBE estimator function
It is known that RBE varies with biological factors such as cell type
and end point, and with physical factors such as dose level and
beam quality [28, 41]. Several studies focusing on the relationship
between RBE and beam quality in proton therapy have been
reported [15, 42–44]. These studies have employed experimental or
computational approaches as beam quality evaluation methods.
In order to evaluate the quality of the proton beams, linear
energy transfer (LET) is more frequently used as the indicator of
RBE than y. This is predominantly because LET is a non-stochastic
quantity and its numerical value is easily calculable, while y is a sto-
chastic quantity and its probability density is difﬁcult to evaluate.
However, the concept of LET cannot express differences in the
track structure around the trajectory of charged particles due to
δ-ray production. Thus, several experiments suggested that ion
Fig. 6. Comparison of RBE and RBE-weighted dose at the central axis in the water phantom after irradiation by the 155MeV
mono-energetic proton beam. The circles and lines represent the published data measured by TEPC [15] and calculated by
PHITS, respectively. Error bars were taken from Ref. [15].
Fig. 7. Comparison of RBE and RBE-weighted dose at the central axis in the water phantom after irradiation by the 155MeV
proton beam with 60 mm SOBP width. The circles and lines represent the published data measured by TEPC [15] and
calculated by PHITS, respectively. Error bars were taken from Ref. [15].
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species dependences can be observed in the relationships between
LET and RBE in surviving cell fractions (e.g. [45, 46]); RBE for
lighter ions is generally higher than that for heavier ions with the
same LET. Therefore, the RBE-estimator function for proton ther-
apy should be adjusted when a LET-based model developed for car-
bon ion therapy is employed in the calculation. In contrast, the
RBE-estimator functions based on y, such as the combination of
PHITS and MKM, should be independent of the type of radiother-
apy, because y can properly represent different track structures
according to ion species. This feature is a great advantage of the y-
based function, and is clearly demonstrated by the agreement
between the calculated and measured RBE-weighted doses shown in
Figs 6 and 7. It should be noted that the tendency of RBE to
increase at the distal fall-off of the clinical SOBP beam has also
been observed in different RBE-estimator functions based on LET
[44, 47].
Signiﬁcance of this research and adaptation for future
clinical application
This is the ﬁrst study to validate the RBE-weighted dose for proton
therapy by a combination of PHITS and MKM. This validation
completes the computational microdosimetric approach based on
the combination of PHITS and MKM for all types of clinical radio-
therapy that require RBE evaluation, i.e. proton therapy, carbon ion
therapy and BNCT.
The RBE-weighted dose calculation algorithm based on MKM
was ofﬁcially implemented in PHITS after version 2.89, allowing
users to calculate the physical and RBE-weighted doses using default
settings. This feature is a great advantage in adapting the calcula-
tions to TPS clinical applications.
A further direction of this study will be to establish the TPS that
takes into account not only the depth distribution shown in this study
but also the lateral distributions with various beam conditions using
the RBE-estimator function in PHITS combined with clinical data for
human body. It can be expected that this work will lead to an expansion
of the adaptation of proton therapies like TOPAS with an RBE-weighted
dose estimator based on Geant4 [8]. Moreover, a combination of
PHITS and MKM is also expected to extend the usefulness of the
RBE-estimator function in the TPS for all kinds of radiotherapies
that require RBE-weighted dose estimation.
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